A Review of Testing for Distinguishing Hashimoto’s Thyroiditis in the Hyperthyroid Stage and Grave’s Disease

References

• Liu H, Zhu Y, Jiao J, et al. ShearWaveelastography for evaluation of the elasticity of Hashimoto’s thyroiditis. Clin Hemorheol Microcirc. 2018:1–8. doi:10.3233/CH-170347
   Google Scholar
• Gu X, Wu S, Xu J, et al. Implication of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patients with thyrotoxicosis: significance in differential diagnosis. Chin J Endocrinol Metab. 2017;33(06):491–496. doi:10.3760/cma.j.issn.1000-6699.2017.06.007
   Google Scholar
• Li T, Zou X, Fan H, et al. A survey on the present status of diagnosis and treatment of graves′ disease in Jiangsu province. Chin J Endocrinol Metab. 2019;35(7):576–580. doi:10.3760/cma.j.issn.1000-6699.2019.07.007
   Google Scholar
• Wan X. Clinical significance of detection of serum thyrotropin receptor antibody in pregnant women with graves’ disease. Electron J Pract Gynecol Endocrinol. 2017;4(01):190–191. doi:10.16484/j.cnki.issn2095-8803.2017.01.111
   Google Scholar
• Shanshan Y, Nan Y. Distribution of IgG subclasses of TgAb and TPOAb in sera from patients with graves′ disease, graves′ disease plus Hashimoto′s thyroiditis and Hashimoto′s thyrotoxicosis. Natl Med J China. 2014;94(2):110–114. doi:10.3760/cma.j.issn.0376-2491.2014.02.008
   Google Scholar
• Weitao W, Runtao M, Gao Shen, et al. Clinical application of thyroid autoantibodies in Hashimoto’s thyroiditis and in graves disease. Chin J Lab Diagn. 2013;17(09):1658–1660.
   Google Scholar
• Kahaly GJ, Diana T, Olivo PD. TSH receptor antibodies: relevance and utility. EndocrPract. 2020;26(1):97–106. doi:10.4158/EP-2019-0363
   Google Scholar
• Diana T, Daiber A, Oelze M, et al. Stimulatory TSH-receptor antibodies and oxidative stress in graves disease. J Clin Endocrinol Metab. 2018;103(10):3668–3677. doi:10.1210/jc.2018-00509
   PubMed Web of Science ®Google Scholar
• Li L, Zang L, Lyu Z, Mu Y. Approach to the Hashimoto thyroiditis patient with thyroid hormone autoantibodies. Chin J Endocrinol Metab. 2020;36(05):421–424. doi:10.3760/cma.j.cn311282-20191220-00564
   Google Scholar
• Cui Z, Wang Z, Liu X, Cai Y, Xu X, Yang T. Establishment of clinical diagnosis model of graves’ disease and Hashimoto’s thyroiditis. J Transl Med. 2019;17(1):11. PMID: 30616573. doi:10.1186/s12967-018-1765-3
   PubMedGoogle Scholar
• Fang Y, Du WH, Zhang CX, et al. The effect of radioiodine treatment on the characteristics of TRAb in graves’ disease. BMC Endocr Disord. 2021;21(1):238. doi:10.1186/s12902-021-00905-4
   PubMed Web of Science ®Google Scholar
• Rong G, Qingzhu W, Wu L, et al. The characteristics and clinical significance of serum TRAb IgG subtype in patients with thyroid associated ophthalmopathy. Chin J Endocrinol Metab. 2020;36(04):315–320. doi:10.3760/cma.j.cn311282-20191030-00457
   Google Scholar
• Zhang L. Ultrasonic features of Hashimoto’s thyroiditis with different thyroid functions. J Mil Surg Southwest China. 2017;19(3):4.
   Google Scholar
• Xu J, Li L, Zhao G, et al. Study on the correlation between ultrasonography and clinical course of Hashimoto’s thyroiditis. Chin J Ultrasound Med. 2019;35(12):3.
   Google Scholar
• Liu X, Liu G. Ultrasonographic manifestations of Hashimoto’sthyroiditis. J Pract Med Imaging. 2017;18(03):257–259. doi:10.16106/j.cnki.cn14-1281/r.2017.03.030
   Google Scholar
• Ge XF, Li L, Cui LG, Xue H. Value of elasticity contrast index of ultrasonography in the diagnosis of Hashimoto’s thyroiditis. Chin J Ultrasound Med. 2015;31(09):772–774.
   Google Scholar
• Wu G, Zou D, Cai H, et al. Ultrasonography in the diagnosis of Hashimoto’s thyroiditis. Front Biosci. 2016;21(5):1006–1012. PMID: 27100487. doi:10.2741/4437
   Google Scholar
• Sarangi PK, Parida S, Mangaraj S, Mohanty BK, Mohanty J, Swain BM. Diagnostic utility of mean peak systolic velocity of superior thyroid artery in differentiating graves’ disease from thyroiditis. Indian J Radiol Imaging. 2021;31(2):311–317. doi:10.1055/s-0041-1734360
   PubMedGoogle Scholar
• Zhao X, Chen L, Li L, et al. Peak systolic velocity of superior thyroid artery for the differential diagnosis of thyrotoxicosis. PLoS One. 2012;7(11):e50051. doi:10.1371/journal.pone.0050051
   PubMed Web of Science ®Google Scholar
• Chen L, Zhao X, Liu H, et al. Mean peak systolic velocity of the superior thyroid artery is correlated with radioactive iodine uptake in untreated thyrotoxicosis. J Int Med Res. 2012;40(2):640–647. doi:10.1177/147323001204000226
   PubMed Web of Science ®Google Scholar
• Uchida T, Takeno K, Goto M, et al. Superior thyroid artery mean peak systolic velocity for the diagnosis of thyrotoxicosis in Japanese patients. Endocr. 2010;J57(5):439–443. doi:10.1507/endocrj.k09e-263
   Google Scholar
• Hiraiwa T, Tsujimoto N, Tanimoto K, Terasaki J, Amino N, Hanafusa T. Use of color Doppler ultrasonography to measure thyroid blood flow and differentiate graves’ disease from painless thyroiditis. Eur Thyroid K. 2013;2(2):120–126. doi:10.1159/000350560
   PubMedGoogle Scholar
• Song F, Zhai Y. Comparative analysis of the application of conventional ultrasound and ultrasound combined with elastography in Graves’ disease and Hashimoto’s thyroiditis. Clin Res. 2021;29(06):131–132.
   Google Scholar
• Zhao W, Hou C, Zhou J, et al. The value of cervical lymph node ultrasound in differentiating graves’ disease from Hashimoto’s thyroiditis. Chin J Curr Adv Gen Surg. 2018;21(09):714–716.
   Google Scholar
• Yangfeng X. Clinical trial of levothyroxine sodium tablets combined with iodine-131 in the treatment of patients with postoperative differentiated thyroid cancer. Chin J Clin Pharmacol. 2020;36(15):2229–2231+2235. doi:10.13699/j.cnki.1001-6821.2020.15.020
   Google Scholar
• Zeng Zhaohui, Qin W, Li X, et al. Study on the early~(131) I uptake rate in patients with Graves disease. Shandong Med J. 2012;52(35):81–82.
   Google Scholar
• Ralli M, Angeletti D, Fiore M, et al. Hashimoto’s thyroiditis: an update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation. AutoimmunRev. 2020;19(10):102649. doi:10.1016/j.autrev.2020.102649
   PubMed Web of Science ®Google Scholar
• Dongdong X, Lun Y, Xun L, et al. Clinical and pathological differences between papillary thyroid carcinoma with Graves′ disease and papillary thyroid carcinoma with Hashimoto′s thyroiditis. Natl Med J China. 2017;97(32):2491–2495. doi:10.3760/cma.j.issn.0376-2491.2017.32.004
   Google Scholar
• Chun W, Shi N, Chonggao W, et al. Cytomorphologic spectrum of Hashimoto’s thyroiditis and its correlation between thyroid functions, Hb, RBC, WBC and PLT. Chin J Lab Diagn. 2021;25(12):1746–1751.
   Google Scholar
• Yuqiu ZHU, Xianyong FANG, Tong ZHANG, et al. Fine needle aspiration cytological features of thyroid papillary carcinoma combined with Hashimoto disease. J Clin Pathol Res. 2018;38(06):1159–1163.
   Google Scholar
• Umar H, Muallima N, Adam J, et al. Hashimoto’s thyroiditis following graves’ disease. ActaMedicaIndonesiana. 2010;42(1):31–35.
   Google Scholar
• Gallo D, Piantanida E, Gallazzi M, et al. Immunological drivers in graves’ disease: NK cells as a master switcher. Front Endocrinol. 2020;11:406. doi:10.3389/fendo.2020.00406
   PubMed Web of Science ®Google Scholar
• Jianyu Z, Yan W, Qing W. Detection and significance of the alteration of Th17 cells in patients with Hashimoto’s thyroiditis and graves’ disease. Chin J Lab Diagn. 2012;16(04):637–640.
   Google Scholar
• Wang D, Chen J, Zhang H, Zhang F, Yang L, Mou Y. Role of different CD40 polymorphisms in graves’ disease and Hashimoto’s thyroiditis. ImmunolInvest. 2017;46(6):544–551. doi:10.1080/08820139.2017.1319382
   Google Scholar
• Oueslati I, Salhi S, Yazidi M, Chaker F, Chihaoui M. A case of Hashimoto’s thyroiditis following graves’ disease. Clin Case Rep. 2022;10(10):e6466. PMID: 36254153; PMCID: PMC9558571. doi:10.1002/ccr3.6466
   PubMed Web of Science ®Google Scholar
• Takasu N, Yamada T, Sato A, et al. Graves’ disease following hypothyroidism due to Hashimoto’s disease: studies of eight cases. Clin Endocrinol. 1990;33(6):687‐698. doi:10.1111/j.1365-2265.1990.tb03906.x
   PubMed Web of Science ®Google Scholar
• Sato T, Takata I, Taketani T, Saida K, Nakajima H. Concurrence of Graves' and Hashimoto’s thyroiditis. Arch Dis Child. 1977;52:951‐955. doi:10.1136/adc.52.12.951
   PubMed Web of Science ®Google Scholar
• Padmanaban P, Jain R. Autoimmune switch from hyperthyroidism to hypothyroidism in graves’ disease. BMJ Case Rep. 2020;13(11):e236465. PMID: 33148577; PMCID: PMC7640471. doi:10.1136/bcr-2020-236465
   PubMedGoogle Scholar
• Sukik A, Mohamed S, Habib MB, et al. The unusual late-onset graves’ disease following Hashimoto’s related hypothyroidism: a case report and literature review. Case Rep Endocrinol. 2020;2020:5647273. PMID: 33489388; PMCID: PMC7787859. doi:10.1155/2020/5647273
   PubMed Web of Science ®Google Scholar
• Daramjav N, Takagi J, Iwayama H, et al. Autoimmune thyroiditis shifting from Hashimoto’s thyroiditis to graves’ disease. Medicina. 2023;59(4):757. PMID: 37109715; PMCID: PMC10141468. doi:10.3390/medicina59040757
   PubMedGoogle Scholar
• Kamath C, Young S, Kabelis K, et al. Thyrotrophin receptor antibody characteristics in a woman with long-standing Hashimoto’s who developed graves’ disease and pretibial myxoedema. Clin Endocrinol. 2012;77(3):465–470. PMID: 22891608. doi:10.1111/j.1365-2265.2012.04397.x
   PubMed Web of Science ®Google Scholar